PeptideJournal
Peptide Profiles20 min read

Fragment 176-191: HGH Fragment Research

Fragment 176-191 represents one of the more fascinating developments in peptide research: a truncated segment of human growth hormone that retains the fat-reducing properties of the parent molecule while shedding its growth-promoting effects.

Fragment 176-191 represents one of the more fascinating developments in peptide research: a truncated segment of human growth hormone that retains the fat-reducing properties of the parent molecule while shedding its growth-promoting effects. Originally identified by researchers at Monash University in the 1990s, this 16-amino-acid sequence emerged from efforts to isolate the specific region of growth hormone responsible for lipolysis—the breakdown of stored body fat.

The concept is elegant. Growth hormone stimulates both growth and fat metabolism, but these two functions can be separated by studying the molecule's structure. Researchers discovered that the C-terminal region of growth hormone, specifically amino acids 176 through 191, controlled fat metabolism without triggering the proliferative effects that make full-length growth hormone problematic for some applications.

What makes Fragment 176-191 particularly interesting is its selectivity. Unlike full-length growth hormone, which affects glucose metabolism, insulin sensitivity, and tissue growth, this fragment appears to target adipose tissue more specifically. It activates lipolysis—the process by which triglycerides are broken down into free fatty acids—while simultaneously inhibiting lipogenesis, the formation of new fat. This dual action, if confirmed through more extensive human studies, could make it a useful tool for studying metabolic regulation and fat metabolism pathways.

Table of Contents

Quick Facts

PropertyDetails
Full NameHuman Growth Hormone Fragment 176-191
Peptide TypeGrowth hormone fragment, lipolytic peptide
Amino Acid Sequence16 amino acids (positions 176-191 of hGH)
Molecular WeightApproximately 1,817 Da
OriginDerived from C-terminal region of human growth hormone
Primary MechanismStimulates lipolysis, inhibits lipogenesis
Half-LifeShort (hours); exact value not well-established in humans
FDA StatusNot approved; research compound only

What Is Fragment 176-191?

Fragment 176-191 is a synthetic peptide consisting of amino acids 176 through 191 of the 191-amino-acid human growth hormone (hGH) molecule. This C-terminal fragment represents the last 16 amino acids of growth hormone, a region that researchers identified as responsible for the hormone's fat-metabolizing effects.

The fragment was discovered and developed during the 1990s by Professor Frank Ng and colleagues at Monash University in Australia. Through systematic analysis of growth hormone's structure, these researchers sought to identify which portions of the molecule controlled specific physiological functions. They found that while the N-terminal region of growth hormone (amino acids 1-134) drove growth and IGF-1 production, the C-terminal segment (176-191) retained lipolytic activity without the accompanying growth-promoting or diabetogenic effects.

The identification of this fragment opened possibilities for more targeted metabolic interventions. By isolating the fat-reducing sequence from the growth-promoting regions, researchers created a molecule that could theoretically influence body composition without the broader systemic effects of full-length growth hormone.

The Relationship to Growth Hormone

Human growth hormone is a 191-amino-acid peptide hormone produced by the pituitary gland. Its effects are wide-ranging: it stimulates growth in children and adolescents, increases muscle mass, improves bone density, and affects metabolism throughout life. Growth hormone also has potent effects on fat metabolism, promoting lipolysis and reducing body fat.

However, growth hormone's multiple effects create complications. The same molecule that reduces fat also:

  • Increases blood glucose levels (diabetogenic effect)
  • Stimulates IGF-1 production, which drives tissue growth
  • Can contribute to insulin resistance with chronic use
  • May cause acromegaly (abnormal growth of hands, feet, and facial features) with prolonged exposure
  • Affects cartilage and connective tissue growth

Fragment 176-191 was developed specifically to separate these functions. By removing the N-terminal and mid-region portions of growth hormone, the fragment retains lipolytic activity while eliminating binding to the classical growth hormone receptor. This means it doesn't trigger IGF-1 production or the growth-promoting cascade that makes long-term growth hormone use problematic for metabolic applications.

In animal studies, Fragment 176-191 stimulates fat breakdown without affecting glucose metabolism or insulin sensitivity—a clear divergence from full-length growth hormone's effects. This selectivity makes the fragment a useful research tool for understanding how growth hormone regulates different metabolic pathways.

Fragment 176-191 vs AOD-9604

Fragment 176-191 and AOD-9604 are closely related but not identical compounds. Understanding the difference is important because much of the available research has been conducted on AOD-9604, and these findings are often extrapolated to Fragment 176-191.

Fragment 176-191 consists of amino acids 176-191 of human growth hormone in their native sequence. This is the unmodified C-terminal fragment.

AOD-9604 (Anti-Obesity Drug 9604) is a modified version developed by the same Monash University research team. AOD-9604 consists of amino acids 177-191 of growth hormone with an additional tyrosine residue added at the N-terminus. The modification was made to improve the peptide's stability and oral bioavailability.

The structural difference is minimal—AOD-9604 is essentially Fragment 176-191 with one amino acid removed from the start and one different amino acid added. However, this small change has practical implications:

  • AOD-9604 underwent formal clinical development, including human trials in the early 2000s
  • AOD-9604 was studied extensively for oral administration
  • Most published research on fat loss effects comes from AOD-9604 studies
  • Fragment 176-191 has less direct human data, with most claims based on animal research or extrapolation from AOD-9604 results

Both peptides work through similar mechanisms and target the same basic function—lipolysis in adipose tissue. Both avoid interaction with the classical growth hormone receptor and neither appears to stimulate IGF-1 production or affect glucose metabolism in the way full-length growth hormone does.

In practical terms, Fragment 176-191 is often presented in the peptide research community as functionally equivalent to AOD-9604, though this claim rests partly on assumption rather than direct comparative studies in humans.

Mechanisms of Action

Fragment 176-191's effects on fat metabolism involve several interconnected pathways, though much of the mechanistic detail comes from animal and cell culture studies rather than human research.

Lipolysis Activation

The primary mechanism centers on stimulating lipolysis—the breakdown of triglycerides stored in adipocytes (fat cells) into free fatty acids and glycerol. This process is controlled by lipase enzymes, particularly hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL).

Fragment 176-191 appears to activate these lipases through a receptor-mediated pathway. The fragment binds to specific receptors on adipocyte surfaces, triggering an intracellular signaling cascade. This pathway involves:

  1. Receptor activation: Fragment 176-191 binds to receptors distinct from the classical growth hormone receptor
  2. cAMP increase: The receptor binding activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP)
  3. Protein kinase A activation: Elevated cAMP activates protein kinase A (PKA)
  4. Lipase phosphorylation: PKA phosphorylates and activates hormone-sensitive lipase
  5. Triglyceride breakdown: Activated lipases hydrolyze stored triglycerides, releasing fatty acids

This mechanism mirrors how other lipolytic hormones (like epinephrine) work, but the specific receptor involved appears to be different from those used by catecholamines or growth hormone.

Beta-3 Adrenergic Receptor Interaction

Research from Monash University and subsequent studies suggests that Fragment 176-191 may work partly through beta-3 adrenergic receptors (β3-AR). These receptors are found primarily in adipose tissue and play a key role in regulating fat breakdown and thermogenesis.

In studies using beta-3 adrenergic receptor knockout mice, AOD-9604 (the modified version of Fragment 176-191) still showed lipolytic effects, though the response was blunted compared to normal mice. This suggests the fragment can work through multiple pathways—both β3-AR-dependent and independent mechanisms contribute to its fat-reducing effects.

Lipogenesis Inhibition

Beyond stimulating fat breakdown, Fragment 176-191 appears to inhibit lipogenesis—the synthesis of new fat from other nutrients. This occurs through downregulation of lipogenic enzymes, particularly acetyl-CoA carboxylase (ACC), which catalyzes the first committed step in fatty acid synthesis.

By simultaneously increasing fat breakdown and decreasing fat formation, the fragment creates a dual effect that shifts the metabolic balance toward fat oxidation.

Absence of Growth Hormone Receptor Binding

Critically, Fragment 176-191 does not bind to or activate the classical growth hormone receptor. This has been confirmed in multiple studies, including research showing that the fragment:

  • Does not stimulate IGF-1 production
  • Does not affect glucose metabolism or insulin sensitivity
  • Does not promote protein synthesis or muscle growth
  • Does not cause the acromegalic effects associated with chronic growth hormone exposure

This selectivity is what distinguishes the fragment from full-length growth hormone. The lipolytic effects occur through a separate receptor system, allowing metabolic effects to be separated from growth-promoting actions.

Metabolic Substrate Shift

Animal studies show that treatment with Fragment 176-191 increases fat oxidation—meaning the body burns a higher proportion of fat as fuel. This substrate shift occurs at the whole-body level, not just in adipose tissue, suggesting the increased availability of fatty acids from lipolysis feeds into systemic energy metabolism.

Research Evidence

Research on Fragment 176-191 spans animal studies, cell culture experiments, and limited human data (mostly derived from AOD-9604 trials). The evidence base is substantially smaller than that for other metabolic peptides like semaglutide or tirzepatide.

Preclinical Studies

Heffernan et al. (2001) published one of the foundational studies in the International Journal of Obesity. This research examined the effects of human growth hormone and AOD-9604 (the modified fragment) on body weight and fat oxidation in obese mice. Both compounds reduced body weight gain in obese animals, but AOD-9604 achieved this without affecting glucose metabolism or insulin sensitivity—a clear departure from full-length growth hormone.

The study found that chronic treatment with AOD-9604 significantly increased fat oxidation rates and stimulated lipolysis in adipose tissue examined ex vivo. Importantly, unlike growth hormone, AOD-9604 showed no adverse effects on insulin sensitivity when measured using euglycemic clamp techniques, considered the gold standard for assessing insulin action.

Ng et al. (2001) examined the effects in Zucker fatty rats, another obesity model. Daily oral dosing with AOD-9604 for 19 days reduced body weight gain by over 50% compared to controls. Adipose tissue from treated animals showed increased lipolytic activity and decreased lipogenic activity when examined in laboratory assays.

Studies in beta-3 adrenergic receptor knockout mice provided insight into the mechanism. Research published in Endocrinology by Heffernan and colleagues showed that both growth hormone and AOD-9604 reduced body weight in normal mice, but the effects were attenuated (though not eliminated) in β3-AR knockout mice. This suggested that Fragment 176-191's mechanism involves β3-AR activation but can also work through alternative pathways.

Cartilage and Joint Health Research

An interesting branch of research has examined Fragment 176-191's effects on cartilage. A study in a rabbit osteoarthritis model, published by Kim et al. (2015), found that weekly intra-articular injections of the fragment increased laboratory markers of cartilage growth. The effects were stronger when the fragment was combined with hyaluronic acid.

This research suggests the fragment may retain some of the regenerative properties attributed to growth hormone, though through mechanisms that remain unclear. The cartilage effects are mechanistically distinct from the lipolytic actions and warrant further investigation.

Cancer Research

A 2022 study published in Drug Design, Development and Therapy investigated Fragment 176-191 in a completely different context: cancer treatment. Researchers examined whether the peptide could improve the effectiveness of doxorubicin, a chemotherapy drug, when loaded together in chitosan nanoparticles.

In MCF-7 breast cancer cells, nanoparticles containing both Fragment 176-191 and doxorubicin showed lower IC50 values (more potent cytotoxicity) than doxorubicin alone. The mechanism appears unrelated to fat metabolism, involving instead the peptide's effects on drug delivery or cellular uptake.

Human Studies: The AOD-9604 Clinical Trial

The most relevant human data comes from a 12-week randomized controlled trial of AOD-9604 conducted in the early 2000s. This Phase II study enrolled approximately 300 obese adults across multiple sites, testing doses ranging from 1 mg to 30 mg daily.

The 1 mg daily dose produced the largest effect: participants lost an average of 2.6-2.8 kg over 12 weeks, compared to 0.8 kg in the placebo group. This difference, while statistically modest, occurred without an intensive diet or exercise intervention.

However, a subsequent larger Phase IIb trial of AOD-9604 failed to demonstrate significant weight loss. This 24-week study in 536 subjects incorporated an intensive diet and exercise program, and under these conditions, AOD-9604 showed no advantage over placebo. The developer, Metabolic Pharmaceuticals, terminated development of AOD-9604 in 2007 following these disappointing results.

The human trial results suggest two possibilities: either the peptide's effects are genuinely modest and insufficient to produce meaningful weight loss in real-world conditions, or the effects are masked when combined with intensive lifestyle interventions that independently drive weight loss.

Research Limitations

Several important limitations affect the Fragment 176-191 evidence base:

  1. Limited human data: Most research has been conducted in mice and rats, with only the AOD-9604 trials providing human data
  2. Conflated compounds: Fragment 176-191 and AOD-9604 are often treated as equivalent, but they differ structurally and have not been directly compared in humans
  3. Terminated development: The failure of AOD-9604 in Phase IIb trials led to cessation of formal development, ending further clinical research
  4. Short study duration: Even the positive 12-week trial was relatively brief for assessing a weight loss intervention
  5. Mechanism uncertainty: While lipolysis activation has been demonstrated in animal tissues, the exact receptor and signaling pathways in humans remain incompletely characterized

Safety and Side Effects

Safety data for Fragment 176-191 specifically is limited, but information from AOD-9604 clinical trials and animal studies provides some insight.

Clinical Trial Safety

In the Phase II trial of AOD-9604, the peptide was described as safe and well-tolerated. The incidence of adverse events in treatment groups was similar to placebo, and no serious adverse events were attributed to the drug. Over 900 participants were exposed to AOD-9604 across six controlled trials, establishing a reasonable short-term safety database.

Notably, AOD-9604 did not cause the side effects typically associated with growth hormone:

  • No increase in blood glucose or insulin resistance
  • No changes in IGF-1 levels
  • No effects on blood pressure (no hypertension)
  • No edema (fluid retention)
  • No signs of acromegaly or abnormal tissue growth

This safety profile aligns with the fragment's mechanism—by avoiding growth hormone receptor activation, it sidesteps the metabolic and proliferative effects that make long-term growth hormone use problematic.

Reported Side Effects

When side effects do occur with Fragment 176-191 or AOD-9604, they are typically mild and transient:

  • Headaches: Potentially related to changes in blood pressure or hydration
  • Increased heart rate and blood pressure: Some users report temporary cardiovascular effects
  • Injection site reactions: Redness, swelling, or discomfort at the injection site
  • Nausea: Occasional gastrointestinal discomfort
  • Muscle or joint pain: Mild musculoskeletal effects

These effects are generally described as short-lived and not severe enough to discontinue use in research contexts.

Theoretical Risks

Several theoretical concerns exist, though direct evidence in humans is lacking:

  • Hormonal imbalance: Long-term effects on the endocrine system are unknown
  • Unknown long-term effects: All available studies are short-term (weeks to months); multi-year safety data does not exist
  • Individual variation: Response to peptides varies, and some individuals might experience atypical reactions
  • Quality control issues: As an unregulated research compound, Fragment 176-191 obtained from non-pharmaceutical sources may have purity or contamination issues

Contraindications and Populations to Avoid

Given the limited human data, Fragment 176-191 should be avoided in:

  • Pregnant or breastfeeding women (no safety data exists)
  • Children and adolescents (potential unknown effects on growth and development)
  • Individuals with cancer or history of malignancy (effects on tumor growth unknown)
  • People with cardiovascular disease (cardiovascular effects inadequately studied)
  • Anyone with active metabolic or endocrine disorders

Comparison to Other Peptides

Fragment 176-191's safety profile appears more favorable than full-length growth hormone, which carries risks of insulin resistance, glucose intolerance, joint pain, and acromegaly with chronic use. However, the fragment also lacks the extensive clinical experience and long-term safety data available for peptides like semaglutide or BPC-157, which have been studied far more extensively.

The absence of serious safety signals in available studies is encouraging but not conclusive. Fragment 176-191 remains a research compound with incomplete safety characterization in humans.

Fragment 176-191 exists in regulatory limbo. Its status varies by jurisdiction and application, but in most cases, it lacks approval for human use.

FDA Status

The U.S. Food and Drug Administration (FDA) has not approved Fragment 176-191 for any medical indication. It is not classified as a drug and has not undergone any part of the FDA's formal drug review process.

As of 2024-2025, the FDA has intensified enforcement against companies selling peptides for human use. The agency issued over 100 warning letters to companies marketing peptides as unapproved drug products. Fragment 176-191 falls squarely within this regulatory action.

Fragment 176-191 can legally be sold and purchased only for research purposes. Marketing or selling the peptide for human consumption violates FDA regulations. Despite this, the peptide is widely available from research chemical suppliers, with the "research use only" designation serving as a legal disclaimer.

The FDA's March 2024 guidance on peptide compounding clarified that peptides can only be legally compounded under specific circumstances, typically when FDA-approved drugs are in shortage. Growth hormone fragments do not qualify for this exception, as they are not approved drugs and no shortage exists.

WADA Prohibited Substance

Both Fragment 176-191 and AOD-9604 appear on the World Anti-Doping Agency (WADA) prohibited list under the category of "growth hormone fragments." They are banned in competitive sports at all times, both in- and out-of-competition.

Athletes subject to WADA testing or any athletic organization's anti-doping policies should understand that use of Fragment 176-191 would constitute a doping violation.

International Status

Fragment 176-191 lacks regulatory approval from health authorities worldwide. It has not been approved in:

  • European Union (EMA)
  • United Kingdom (MHRA)
  • Canada (Health Canada)
  • Australia (TGA)

The peptide remains an unregulated research compound in virtually all jurisdictions.

Implications for Users

The lack of regulatory approval means:

  1. No quality control: Products sold as Fragment 176-191 are not subject to pharmaceutical manufacturing standards
  2. No medical oversight: Use occurs outside the medical system, without physician supervision
  3. No recourse: If adverse effects occur, users have limited legal recourse
  4. Legal risk: Depending on jurisdiction and specific circumstances, possession or use might carry legal risks

Anyone considering Fragment 176-191 should understand that it is an unregulated research compound operating in a legal gray area. It is not a legitimate pharmaceutical product and cannot be prescribed by medical practitioners in most countries.

Frequently Asked Questions

What is Fragment 176-191 used for?

Fragment 176-191 is studied primarily as a research compound for its effects on fat metabolism. In animal studies, it stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), leading to reduced body fat accumulation. However, it is not approved for any medical use in humans. Some individuals use it experimentally for body composition goals, but this occurs outside regulated medical practice.

How is Fragment 176-191 different from growth hormone?

Fragment 176-191 consists of only the last 16 amino acids (positions 176-191) of the full 191-amino-acid growth hormone molecule. This C-terminal fragment retains growth hormone's fat-metabolizing effects but does not bind to the growth hormone receptor. As a result, Fragment 176-191 stimulates lipolysis without causing the growth-promoting, IGF-1-stimulating, or diabetogenic effects associated with full-length growth hormone. It's a more selective compound focused specifically on fat metabolism.

What's the difference between Fragment 176-191 and AOD-9604?

The two peptides are structurally very similar. Fragment 176-191 is the unmodified sequence from positions 176-191 of growth hormone. AOD-9604 is a modified version consisting of positions 177-191 (one amino acid shorter) with an additional tyrosine residue added at the N-terminus. This modification was made to improve stability and oral bioavailability. AOD-9604 underwent formal clinical development and has more human research data, while Fragment 176-191 research is mostly in animals. They're often treated as functionally equivalent, though direct comparative studies in humans are lacking.

Does Fragment 176-191 cause the side effects of growth hormone?

Fragment 176-191 appears to avoid the major side effects associated with full-length growth hormone. Studies of AOD-9604 (the closely related modified fragment) showed no effects on blood glucose, insulin sensitivity, IGF-1 levels, or blood pressure—all common concerns with growth hormone use. The fragment doesn't cause acromegaly, edema, or glucose intolerance because it doesn't activate the growth hormone receptor. However, mild side effects like headaches, temporary increases in heart rate, and injection site reactions have been reported.

How effective is Fragment 176-191 for fat loss in humans?

The human evidence is limited and mixed. A 12-week trial of AOD-9604 (the modified version) showed modest weight loss of about 2.6 kg compared to 0.8 kg for placebo. However, a larger 24-week trial that included intensive diet and exercise found no significant difference between AOD-9604 and placebo. These results suggest that if Fragment 176-191 has fat loss effects in humans, they are modest at best. Most of the stronger evidence comes from animal studies, which may not translate directly to human metabolism.

Is Fragment 176-191 legal to use?

Fragment 176-191 is not FDA-approved for any use and can only be legally sold for research purposes in most countries. Marketing or selling it for human consumption violates regulations in the United States and most other jurisdictions. It also appears on the World Anti-Doping Agency (WADA) prohibited list as a growth hormone fragment, making it banned in competitive sports. While it's available from research chemical suppliers, using it falls into a regulatory gray area without medical oversight or quality control.

How is Fragment 176-191 administered?

In research settings and animal studies, Fragment 176-191 is typically administered via subcutaneous injection. AOD-9604, the modified version, was studied both as an injection and as an oral formulation (the modification was partly intended to improve oral bioavailability). The peptide has a short half-life measured in hours, so protocols generally involve daily administration. Dosing regimens in human studies ranged from 1 mg to 30 mg daily, with the 1 mg dose showing the best results in the initial trial.

Can Fragment 176-191 help with muscle growth?

Fragment 176-191 does not appear to promote muscle growth. Unlike full-length growth hormone, which stimulates protein synthesis and muscle hypertrophy partly through IGF-1 induction, Fragment 176-191 does not bind to the growth hormone receptor and does not affect IGF-1 levels. Its effects are specific to fat metabolism—lipolysis and lipogenesis—rather than muscle tissue. Peptides like CJC-1295 or ipamorelin that increase endogenous growth hormone production would be more relevant to muscle-building research.

What other peptides are similar to Fragment 176-191?

Several other peptides target fat metabolism or growth hormone pathways. AOD-9604 is the closest analog—essentially a modified version of Fragment 176-191 with slightly different structure. Growth hormone secretagogues like CJC-1295, ipamorelin, sermorelin, and MK-677 increase endogenous growth hormone production rather than isolating specific fragments. For metabolic effects and weight management, GLP-1 receptor agonists like semaglutide, tirzepatide, and mazdutide operate through completely different mechanisms but have robust clinical evidence for fat loss.

The Bottom Line

Fragment 176-191 represents an interesting proof-of-concept in peptide research: the idea that specific functions of a larger hormone can be isolated by identifying the responsible structural region. By extracting amino acids 176-191 from the 191-amino-acid growth hormone molecule, researchers created a peptide that stimulates fat breakdown while avoiding the growth-promoting, IGF-1-inducing, and diabetogenic effects of the full hormone.

The animal research is promising. Studies in obese mice and rats demonstrate that Fragment 176-191 (and its modified analog AOD-9604) reduce body weight gain, increase fat oxidation, and stimulate lipolysis without affecting glucose metabolism or insulin sensitivity. The fragment appears to work through a mechanism involving beta-3 adrenergic receptors and activation of hormone-sensitive lipase, creating a dual effect of increased fat breakdown and decreased fat formation.

However, the human evidence is far more limited. AOD-9604, which has been studied more extensively than Fragment 176-191 itself, showed modest weight loss in an initial 12-week trial but failed to demonstrate efficacy in a larger, longer trial that included diet and exercise interventions. These results led to termination of clinical development in 2007, effectively ending further formal research.

Fragment 176-191 exists in regulatory limbo. It is not FDA-approved for any use and lacks approval from health authorities worldwide. It can only be legally sold for research purposes, though it remains available from research chemical suppliers. Quality control, purity, and consistency are concerns given the lack of pharmaceutical-grade manufacturing standards.

The safety profile appears favorable in short-term studies—notably lacking the growth hormone-related side effects like glucose intolerance and IGF-1 elevation—but long-term safety data in humans is essentially nonexistent. The peptide should be considered an unproven research compound with incomplete characterization rather than a validated therapeutic agent.

For individuals interested in metabolic peptides with robust clinical evidence, FDA-approved options like semaglutide or tirzepatide offer well-characterized efficacy and safety profiles, established manufacturing standards, and medical oversight. For those interested in growth hormone pathways, FDA-approved GHRH analogs like tesamorelin provide a regulated alternative.

Fragment 176-191 remains an intriguing research compound with a scientifically sound rationale and supportive animal data, but one that lacks the human evidence and regulatory approval needed to recommend it for practical use. Its primary value lies in what it teaches us about growth hormone's structure-function relationships and the possibility of developing more selective metabolic modulators in the future.

Disclaimer: This article is for educational and informational purposes only. It is not medical advice. Fragment 176-191 is not FDA-approved for human use and should not be used outside of legitimate research settings. Peptide use should only occur under the supervision of a qualified healthcare provider in jurisdictions where such use is legal. Always consult with a medical professional before considering any peptide therapy.

References

  1. Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. https://pubmed.ncbi.nlm.nih.gov/11673763/

  2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. https://pubmed.ncbi.nlm.nih.gov/11713213/

  3. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. https://pubmed.ncbi.nlm.nih.gov/11146367/

  4. Ng FM, Adamafio NA, Gale C. Effects of growth hormone treatment on the insulin sensitivity of glucose metabolism in obese (fa/fa) Zucker rats. Horm Res. 2000;54(5-6):280-286. https://pubmed.ncbi.nlm.nih.gov/11116208/

  5. Kim SJ, Kim JH, Lee DW, et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-432. https://pubmed.ncbi.nlm.nih.gov/26275694/

  6. Mokhtari T, Akbarzadeh A, Rezaei-Sadabady R, et al. Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des Devel Ther. 2022;16:2033-2046. https://pubmed.ncbi.nlm.nih.gov/35783198/

  7. Ng FM, Heffernan MA. AOD9604 (Metabolic Pharmaceuticals). Curr Opin Investig Drugs. 2003;4(10):1185-1190.

  8. Wu Z, Bidlingmaier M, Friess SC, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2014;6(11-12):1191-1199. https://pubmed.ncbi.nlm.nih.gov/25208511/

  9. Obesity drug codenamed AOD9604 highly successful in trials. News-Medical.Net. 2004. https://www.news-medical.net/news/2004/12/16/6878.aspx

  10. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23(5):623-646.

  11. Fain JN, Bahouth SW. Regulation of leptin release by mammalian adipose tissue in vitro. Biochem Biophys Res Commun. 1998;247(3):654-658.

  12. Moré M, Hurtado del Pozo C, Ramos-Píriz JM, et al. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2024;14(1):1-15. https://jofem.org/index.php/jofem/article/view/213/278

  13. Obesity Pharmacotherapy: Current Perspectives and Future Directions. Am J Cardiovasc Drugs. 2013;13(1):13-22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/

  14. World Anti-Doping Agency. Prohibited List 2026. https://www.wada-ama.org/

  15. U.S. Food and Drug Administration. FDA warns companies marketing unapproved peptide products. 2024-2025. https://www.fda.gov/

  16. Ng FM, Adamafio NA, Gale C. Oral administration of a synthetic fragment of human growth hormone stimulates lipolysis and reduces body fat in obese mice. J Endocrinol. 2000;167(3):R9-R11.

  17. Stannard SR, Thompson MW, Fairbairn K, et al. Fasting for 72 h increases intramyocellular lipid content in nondiabetic, physically fit men. Am J Physiol Endocrinol Metab. 2002;283(6):E1185-E1191.

  18. Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci. 2003;24(6):276-283.

  19. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab. 2005;19(4):471-482.

  20. Xu X, Ying Z, Cai M, et al. Exercise ameliorates high-fat diet-induced metabolic and vascular dysfunction, and increases adipocyte progenitor cell population in brown adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2011;300(5):R1115-R1125.